These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3111689)

  • 21. Experience of long term treatment and different dosage regimens of isosorbide 5-mononitrate.
    Meffert M; Paeckelmann IM
    Drugs; 1987; 33 Suppl 4():104-10. PubMed ID: 3622314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of coronary heart disease with isosorbide mononitrate ('Elantan' 20).
    van Hasselt M; Weiss M; Haase W
    Curr Med Res Opin; 1984; 9(2):107-12. PubMed ID: 6443348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The effect of time and dosage of isosorbide mononitrate on objective and subjective parameters in angina pectoris].
    Herrmann H; Kuhl A; Maier-Lenz H
    Arzneimittelforschung; 1988 May; 38(5):694-8. PubMed ID: 3415710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled release isosorbide-5-mononitrate in angina pectoris: a comparison with standard formulation isosorbide dinitrate.
    Parker JO
    Can J Cardiol; 1991 Apr; 7(3):125-30. PubMed ID: 2044014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Lack of tolerance development in interval therapy with 50 mg isosorbide-5-nitrate retard (Elantan long)].
    Jansen W; Prenzel R; Kümper H; Weidmann B; Tauchert M
    Z Kardiol; 1989; 78 Suppl 2():72-8; discussion 115-7. PubMed ID: 2511697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the antianginal effect of isosorbide-5-mononitrate in patients with chronic stable angina pectoris.
    Yasky J; Ontanilla E; Koch JE
    Cardiology; 1991; 79 Suppl 2():27-30. PubMed ID: 1760826
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dose-effect relationship amongst three different sustained-release forms of isosorbide 5-mononitrate in patients with coronary artery disease.
    Kenedi P; Gathmann-Lewik U
    Cardiology; 1987; 74 Suppl 1():29-33. PubMed ID: 3300975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-ischaemic response to sublingual nitroglycerin during oral administration of isosorbide dinitrate in patients with stable angina pectoris: when does cross-tolerance occur?
    Kośmicki MA; Szwed H; Sadowski Z
    Cardiovasc Drugs Ther; 2004 Jan; 18(1):47-55. PubMed ID: 15115903
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of angina pectoris with isosorbide-5-mononitrate. A multicenter study in general practice.
    Beck EJ; Koch JE
    Cardiology; 1991; 79 Suppl 2():41-5. PubMed ID: 1760828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical effects of a sustained-release preparation of isosorbide dinitrate on angina pectoris.
    Arakawa K; Fujino M
    Clin Ther; 1980; 3(2):103-16. PubMed ID: 6778614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of tolerance after chronic administration of controlled-release isosorbide-5-mononitrate. Interaction of nitrate and gallopamil.
    Stauch M; Grossmann G; Wanjura D; Adam WE
    Eur J Clin Pharmacol; 1990; 38 Suppl 1():S31-4. PubMed ID: 2354712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Anti-ischemic efficacy of sustained-release isosorbide-5-mononitrate: echocardiography during mental and physical stress].
    Keck M; Tretter R; Sauerbrey-Wullkopf N
    Z Kardiol; 2001 Oct; 90(10):766-73. PubMed ID: 11757473
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.
    Bonn R
    Am J Cardiol; 1988 Mar; 61(9):12E-14E. PubMed ID: 3348135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
    Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
    Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antianginal effect of transdermal nitroglycerin and oral nitrates given for 24 hours a day in 2,456 patients with stable angina pectoris. The Italian Multicenter Study.
    Savonitto S; Motolese M; Agabiti-Rosei E
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):194-203. PubMed ID: 7620688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Isosorbide-5-mononitrate--effective monotherapy in chronic stable angina.
    Akhras F; Jefferies S; Jackson G
    Z Kardiol; 1985; 74 Suppl 4():16-20. PubMed ID: 3938114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Slow release isosorbide-5-mononitrate therapy in angina pectoris. Effects of exercise performance and hemodynamics.
    Jansen W; Prenzel R; Rappert B; Kümper H; Laufen H; Tauchert M
    Cardiology; 1991; 79 Suppl 2():78-85. PubMed ID: 1760835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate.
    Bharani A; Ganguli A; Mathur LK; Jamra Y; Raman PG
    Indian Heart J; 2002; 54(2):170-5. PubMed ID: 12086380
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of antianginal efficacy of long-acting sustained release isosorbide dinitrate in comparison with short-acting isosorbide dinitrate.
    Rao YV; Reddy KS; Wasir HS
    Indian Heart J; 1991; 43(2):97-100. PubMed ID: 1752623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical experience with Imdur in angina pectoris. A review.
    Nyberg G
    Eur J Clin Pharmacol; 1990; 38 Suppl 1():S65-8. PubMed ID: 1972359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.